Lifecore Biomedical
LFCR
96 hedge funds and large institutions have $288M invested in Lifecore Biomedical in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 32 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
13% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 32
9% more capital invested
Capital invested by funds: $265M → $288M (+$23.3M)
0% more funds holding
Funds holding: 96 → 96 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.55% less ownership
Funds ownership: 93.34% → 90.79% (-2.6%)
62% less call options, than puts
Call options by funds: $10K | Put options by funds: $26K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$6.35M |
| 2 |
CSC
Cove Street Capital
El Segundo,
California
|
+$4.74M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$3.43M |
| 4 |
AC
AltraVue Capital
Bellevue,
Washington
|
+$2.19M |
| 5 |
BlackRock
New York
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
-$14.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.2M |
| 3 |
WC
Walthausen & Co
Malta,
New York
|
-$1.14M |
| 4 |
WPC
White Pine Capital
Bloomington,
Minnesota
|
-$1.07M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$804K |
LFCR Hedge Fund Activity: Q4 2020 in Review
96 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2020, worth a combined $288M — up 8.8% from $265M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LFCR positions and 8 closed out — a net gain of 1 holder — while 36 added to existing stakes and 32 trimmed.
The largest buyer was Kennedy Capital Management, adding an estimated $6.35M. The largest seller was Russell Investments Group, cutting an estimated $14.4M.
- 96 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $288M of Lifecore Biomedical stock for Q4 2020, up 8.8% quarter-over-quarter.
- 9 funds opened new Lifecore Biomedical positions in Q4 2020 and 8 closed out, a net change of +1 holder.
- The largest Lifecore Biomedical buyer in Q4 2020 was Kennedy Capital Management, an estimated $6.35M added.
- The largest Lifecore Biomedical seller in Q4 2020 was Russell Investments Group, an estimated $14.4M sold.
Based on aggregated 13F filings for Q4 2020.